Pixantrone (BBR 2778) versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial
ESTADO CLÍNICO
En marcha
FASE/S DEL ENSAYO
Fase III
PATOLOGÍA
Linfoma Hodgkin, Linfoma no Hodgkin, Terapia celular y T-CARs, Trasplante de progenitores hematopoyéticos, EICH, Linfoma Folicular, Linfoma
FECHA DE APERTURA
Abril, 2005
FECHA DE CIERRE
,
CRITERIOS DE INCLUSIÓN
Non-Hodgkin's Lymphoma
CRITERIOS DE EXCLUSIÓN
No especificado
DESCRIPCIÓN
Complete response (CR) and unconfirmed Complete response (CRu) rate: The total proportion of patients with CR or CRu.CR and CRu will be defined according to the report of the international workshop to standardize response criteria for NHL.
PALABRAS CLAVE
autologous, autologous transplant, cd20, diffuse large b-cell lymphoma (dlbcl), dlbcl, engraftment, follicular lymphoma, gvhd, hodgkin, hodgkin lymphoma, linfoma, linfoma de hodgkin, linfoma no hodgkin, linfoma t, lymphoma, non-hodgkin lymphoma, stem cell, t-cell lymphoma
